Latest News and Press Releases
Want to stay updated on the latest news?
-
Lewes, Delaware, April 13, 2026 (GLOBE NEWSWIRE) -- The Global Seismic Survey Market was valued at USD 20.88 Billion in 2024 and is projected to reach USD 30.15 Billion by 2032, growing at a CAGR of...
-
BOSTON, April 13, 2026 (GLOBE NEWSWIRE) -- Merlin, Inc. (NASDAQ: MRLN), an aerospace and defense technology company building the operating system of record for autonomous flight, today announced the...
-
New York, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor (MMR) and technology...
-
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need ...
-
Safe Pro Launches Next Gen AI Powered NODE-X Miniaturized Edge Processing for Drone Footage at U.S. Army Exercise
-
AMARILLO, Texas, April 13, 2026 (GLOBE NEWSWIRE) -- Take 5 Oil Change, a leading provider of fast, friendly, and simple car maintenance, announced today the grand opening of its newest Amarillo shop...
-
SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) -- Some 45 years ago, the first cases of AIDS appeared in New York, and then, everywhere. Three years later, Human Immunodeficiency Virus (HIV) was...
-
West Bend, WI, April 13, 2026 (GLOBE NEWSWIRE) -- The U.S. Concealed Carry Association (USCCA) today strongly supports Secretary of War Pete Hegseth’s announcement authorizing expanded personal...
-
Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Ammunition Market by Rifle, Handgun, Autocannon, Artillery, Tank, Mortar, Naval, Rocket - Global Forecast to 2031" has been added to ...
-
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...